Skip to Content


In the US, Busulfan (busulfan systemic) is a member of the drug class alkylating agents and is used to treat Bone Marrow Transplantation, Chronic Myelogenous Leukemia and Thrombocythemia.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Cytostatic alkylating agent

Chemical Name

1,4-Butanediol, dimetanesulfonate

Foreign Names

  • Busulfanum (Latin)
  • Busulfan (German)
  • Busulfan (French)
  • Busulfano (Spanish)

Generic Names

  • Busulfan (OS: BAN, DCF, JAN)
  • BUS (IS)
  • CB 2041 (IS)
  • GT 41 (IS)
  • Myelosanum (IS: USSRP)
  • Tetramethylendi(methansulfonat) (IS: IUPAC)
  • Busulfan (PH: BP 2016, JP XVI, Ph. Eur. 8, Ph. Int. 4, USP 38)
  • Busulfanum (PH: Ph. Eur. 8, Ph. Int. 4)

Brand Names

  • Busilvex
    Pierre Fabre, Austria; Pierre Fabre, Belgium; Pierre Fabre, Switzerland; Pierre Fabre, Czech Republic; Pierre Fabre, Germany; Pierre Fabre, Denmark; Pierre Fabre, Egypt; Pierre Fabre, Finland; Pierre Fabre, United Kingdom; Pierre Fabre, Greece; Pierre Fabre, Hungary; Pierre Fabre, Ireland; Pierre Fabre, Lebanon; Pierre Fabre, Lithuania; Pierre Fabre, Poland; Pierre Fabre, Sweden; Pierre Fabre, Turkey; Pierre Fabre Iberica, Spain; Pierre Fabre Medicament, Slovenia; Pierre Fabre Medicament, Slovakia; Pierre Fabre Médicament, France; Pierre Fabre Pharma Norden, Norway; Rovafarm, Argentina; Tema Medical, South Africa
  • Busulf
    Pharmedic, Pakistan
  • Busulfan Aspen
    Aspen, United Kingdom
  • Busulfan Fresenius Kabi
    Fresenius Kabi, Poland; Fresenius Kabi, Slovenia
  • Busulfan Varifarma
    Varifarma, Argentina
  • Busulfano Allen
    Allen, Spain
  • Busulfex
    China Otsuka, China; Korea Otsuka Pharmaceutical, South Korea; Kyowa Hakko Kirin, China; Orphan, Australia; Otsuka, Canada; Otsuka, Hong Kong; Otsuka, Israel; Otsuka, Malaysia; Otsuka, Singapore; Otsuka America Pharmaceuticals, United States; Otsuka Pharmaceutical, Japan; PDL, Taiwan; Thai Otsuka, Thailand
  • Mablin 1%
    Ohara Yakuhin, Japan
  • Mylefan
    Cadila HC, India
  • Myleran
    Aspen, Australia; Aspen, Belgium; Aspen, Estonia; Aspen, Ireland; Aspen, Iceland; Aspen, Lithuania; Aspen, Malaysia; Aspen, Netherlands; Aspen, New Zealand; Aspen, Poland; Aspen, Romania; Aspen Europe, Austria; Aspen Labs, Mexico; Aspen Pharma, Germany; Aspen Pharmacare, Hong Kong; Aspri Pharma, Canada; Excella, Bulgaria; Excella, Israel; Genopharm, Czech Republic; Glaxo Smithkline, Lebanon; Glaxo Wellcome, Portugal; GlaxoSmithKline, Argentina; GlaxoSmithKline, Bangladesh; GlaxoSmithKline, Brazil; GlaxoSmithKline, China; GlaxoSmithKline, Egypt; GlaxoSmithKline, India; GlaxoSmithKline, Oman; GlaxoSmithKline, Taiwan; GlaxoSmithKline, United States; GlaxoSmithKline, South Africa; HAC Pharma, France; L. Molteni & C. dei F.lli Alitti Società di Esercizio, Italy; PharmaSwiss, Slovenia; Pharmatech Chile, Chile; Vitaflo, Sweden; VLD, Turkey
  • Myléran
    The Wellcome Foundation Limited, Tunisia


BANBritish Approved Name
DCFDénomination Commune Française
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.